Enzymogen

Company Overview

Snapshot

Founded in April 2015 by Avi Wener and Meir Azulay, Enzymogen operates with 1–10 employees. The company ceased operations in September 2022.

Business overview

Enzymogen is a Health Tech & Life Sciences company that developed a technology platform for manufacturing medical-grade cannabinoids. The company utilized enzymatic processes to convert natural resources into commercially viable products, aiming to improve the efficiency of existing products and maximize commercially viable byproducts. Enzymogen's core functions included full-package projects from clone to final enzyme, clone development across various organisms, process development and optimization, fermenter/bioreactor scale-up, establishment of analytical methods, and GMP manufacturing. Its product offerings included Taq DNA polymerase, human gastric lipase, phospholipase C and D, and cholesterol esterase YEH1 and TGL1, serving the pharmaceuticals, pain-relief, cannabis, and medical-cannabis sectors.

Company Intelligence Q&A

What is Enzymogen's primary focus?

Enzymogen focuses on developing a technology platform for manufacturing medical-grade cannabinoids using enzymatic processes to convert natural resources into commercially viable products.

When was Enzymogen founded?

Enzymogen was founded in April 2015.

Who are the co-founders of Enzymogen?

Enzymogen was co-founded by Avi Wener and Meir Azulay.

What is the current status of Enzymogen?

Enzymogen is currently non-active and ceased to operate in September 2022.

What types of products did Enzymogen offer?

Enzymogen's product offerings included Taq DNA polymerase (nonbacterial source), human gastric lipase, phospholipase C and D, and cholesterol esterase YEH1 and TGL1.